CYTEIR THERAPEUTICS, INC. [•] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • June 4th, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations • New York
Cyteir Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
INDEMNIFICATION AGREEMENTIndemnification Agreement • May 28th, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of , 2021 between Cyteir Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • August 8th, 2022 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations • New York
CYTEIR THERAPEUTICS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of [ ], [ ]Indenture • August 8th, 2022 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations • New York
INDENTURE, dated as of [ ], [ ] by and between Cyteir Therapeutics, Inc., a Delaware corporation, as Issuer (the “Company”) and U.S. Bank Trust Company, National Association, as Trustee (the “Trustee”).
CYTEIR THERAPEUTICS, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • June 14th, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a stock option granted by Cyteir Therapeutics, Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Cyteir Therapeutics, Inc. 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
CYTEIR THERAPEUTICS, INC. LEDGEMONT RESEARCH CENTER LEXINGTON, MALease Agreement • March 26th, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations
CYTEIR THERAPEUTICS, INC. NON-STATUTORY STOCK OPTION AGREEMENTNon-Statutory Stock Option Agreement • June 14th, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a stock option granted by Cyteir Therapeutics, Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Cyteir Therapeutics, Inc. 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
EMPLOYMENT AGREEMENTEmployment Agreement • May 10th, 2023 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations
This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of April 15, 2022 by and between Cyteir Therapeutics, Inc. (the “Company”) and Adam Veness (the “Executive”), and effective as of the Effective Date (as defined below).
CYTEIR THERAPEUTICS, INC. RESTRICTED STOCK AGREEMENTRestricted Stock Agreement • May 28th, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Restricted Stock Agreement (the “Agreement”) is entered into as of the effective date set forth on the signature page hereto (the “Effective Date”) by and between Cyteir Therapeutics, Inc., a Delaware corporation (the “Company”), and the person executing a counterpart signature page hereto (referred to herein as “Founder”).
CYTEIR THERAPEUTICS, INC. NON-QUALIFIED STOCK OPTION AGREEMENTNon-Qualified Stock Option Agreement • May 28th, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This option satisfies in full all commitments that the Company has to the Optionee with respect to the issuance of stock, stock options or other equity securities. By signing below, the Optionee agrees to the terms and conditions set forth in this Agreement and in the Plan.
CYTEIR THERAPEUTICS, INC. SECOND AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT FEBRUARY 5, 2021Investors’ Rights Agreement • May 28th, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Second Amended and Restated Investors’ Rights Agreement (the “Agreement”) is made as of February 5, 2021, by and among Cyteir Therapeutics, Inc., a Delaware corporation (the “Company”) and each of the individuals and entities listed on Schedule A (together with any subsequent investors, or transferees, who become parties hereto pursuant to Subsection 6.9 below, the “Investors”).
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • May 28th, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Amended and Restated Employment Agreement (the “Agreement”), dated as of May 25, 2021 (the “Effective Date”), is by and between Cyteir Therapeutics, Inc., a Delaware corporation (the “Company”) and Markus Renschler (the “Executive”).
LEDGEMONT TECHNOLOGY CENTER Lexington, Massachusetts FOURTH AMENDMENT TO LEASE CYTEIR THERAPEUTICS, INC.Lease • October 5th, 2023 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations
Fourth Amendment to Lease (“Fourth Amendment”) dated as of October 3 , 2023 between 99 Hayden LLC, a Delaware limited liability company (“Landlord”), and Cyteir Therapeutics, Inc., a Delaware corporation (“Tenant”).
CYTEIR THERAPEUTICS, INC. NON-STATUTORY STOCK OPTION AGREEMENT (NON-EMPLOYEE DIRECTORS)Non-Statutory Stock Option Agreement • June 14th, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations
This agreement (this “Agreement”) evidences a stock option granted by Cyteir Therapeutics, Inc. (the “Company”) to the individual named above (the “Participant”), pursuant to and subject to the terms of the Cyteir Therapeutics, Inc. 2021 Equity Incentive Plan (as from time to time amended and in effect, the “Plan”). Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.
LEASE AMENDMENT AND TERMINATION AGREEMENTLease Amendment and Termination Agreement • April 3rd, 2023 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations
THIS LEASE AMENDMENT AND TERMINATION AGREEMENT (“Agreement”) is made as of March 29, 2023 (“Effective Date”), by and between 99 HAYDEN LLC, a Delaware limited liability company (“Landlord”), and CYTEIR THERAPEUTICS, Inc., a Delaware corporation (“Tenant”).
CYTEIR THERAPEUTICS, INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • May 28th, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This option satisfies in full all commitments that the Company has to the Optionee with respect to the issuance of stock, stock options or other equity securities. By signing below, the Optionee agrees to the terms and conditions set forth in this Agreement and in the Plan.
LEDGEMONT TECHNOLOGY CENTER Lexington, Massachusetts SECOND AMENDMENT TO LEASE CYTEIR THERAPEUTICS, INC.Lease • July 2nd, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
Second Amendment to Lease (“Second Amendment”) dated as of July 1, 2021 between 99 Hayden LLC, a Delaware limited liability company, successor-in-interest to 128 Spring Street Lexington, LLC, a Delaware limited liability company (“Landlord”), and Cyteir Therapeutics, Inc. a Delaware corporation (“Tenant”).
FIRST AMENDMENT TO LEASELease • March 26th, 2021 • Cyteir Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Lease (“First Amendment”) is executed as of the 15th day of October, 2019, by and between 128 Spring Street Lexington, LLC, as landlord (“Landlord”) and Cyteir Therapeutics, Inc., as tenant (“Tenant”).
